BR112022017832A2 - Inibidores de replicação do vírus da imunodeficiência humana - Google Patents
Inibidores de replicação do vírus da imunodeficiência humanaInfo
- Publication number
- BR112022017832A2 BR112022017832A2 BR112022017832A BR112022017832A BR112022017832A2 BR 112022017832 A2 BR112022017832 A2 BR 112022017832A2 BR 112022017832 A BR112022017832 A BR 112022017832A BR 112022017832 A BR112022017832 A BR 112022017832A BR 112022017832 A2 BR112022017832 A2 BR 112022017832A2
- Authority
- BR
- Brazil
- Prior art keywords
- immunodeficiency virus
- human immunodeficiency
- virus replication
- replication inhibitors
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062985937P | 2020-03-06 | 2020-03-06 | |
| US202063040051P | 2020-06-17 | 2020-06-17 | |
| PCT/IB2021/051764 WO2021176366A1 (en) | 2020-03-06 | 2021-03-03 | Inhibitors of human immunodeficiency virus replication |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022017832A2 true BR112022017832A2 (pt) | 2022-11-01 |
Family
ID=74859494
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022017832A BR112022017832A2 (pt) | 2020-03-06 | 2021-03-03 | Inibidores de replicação do vírus da imunodeficiência humana |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230355626A1 (enExample) |
| EP (1) | EP4114834A1 (enExample) |
| JP (1) | JP2023517043A (enExample) |
| KR (1) | KR20220151655A (enExample) |
| CN (1) | CN115551858A (enExample) |
| AU (2) | AU2021231447A1 (enExample) |
| BR (1) | BR112022017832A2 (enExample) |
| CA (1) | CA3170536A1 (enExample) |
| CL (1) | CL2022002405A1 (enExample) |
| IL (1) | IL296182A (enExample) |
| MX (1) | MX2022011016A (enExample) |
| WO (1) | WO2021176366A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202128648A (zh) * | 2019-10-04 | 2021-08-01 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| US20250042926A1 (en) | 2023-05-31 | 2025-02-06 | Gilead Sciences, Inc. | Therapeutic compounds for hiv |
| CN121335877A (zh) | 2023-06-15 | 2026-01-13 | Viiv保健英国第五有限公司 | 用于制备化合物的方法和中间体 |
| TW202547514A (zh) * | 2024-02-05 | 2025-12-16 | 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102464654B (zh) | 2010-11-12 | 2016-01-13 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| AU2012278976B2 (en) | 2011-07-06 | 2017-05-11 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
| CN102863512B (zh) | 2011-07-07 | 2016-04-20 | 上海泓博智源医药技术有限公司 | 抗病毒化合物 |
| ES2642265T3 (es) | 2013-01-09 | 2017-11-16 | Gilead Sciences, Inc. | Compuestos terapéuticos para el tratamiento de infecciones virales |
| TW201443037A (zh) | 2013-01-09 | 2014-11-16 | Gilead Sciences Inc | 治療用化合物 |
| US9220710B2 (en) | 2013-01-09 | 2015-12-29 | Gilead Sciences, Inc. | Therapeutic compounds |
| TWI694071B (zh) | 2013-03-01 | 2020-05-21 | 美商基利科學股份有限公司 | 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物 |
| AU2014340110B2 (en) | 2013-10-24 | 2018-07-12 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| US10202353B2 (en) | 2014-02-28 | 2019-02-12 | Gilead Sciences, Inc. | Therapeutic compounds |
| WO2015130966A1 (en) | 2014-02-28 | 2015-09-03 | Gilead Sciences, Inc. | Antiviral agents |
| EP3186239B1 (en) | 2014-08-29 | 2018-10-10 | Gilead Sciences, Inc. | Antiretroviral agents |
| US9855230B2 (en) | 2014-09-09 | 2018-01-02 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| WO2016172425A1 (en) | 2015-04-23 | 2016-10-27 | Viiv Healthcare (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| US10221129B2 (en) | 2015-04-23 | 2019-03-05 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| CN119462611A (zh) | 2016-08-19 | 2025-02-18 | 吉利德科学公司 | 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物 |
| TW201906834A (zh) * | 2017-05-02 | 2019-02-16 | 英商Viiv醫療保健英國(No.5)有限公司 | 人類免疫不全病毒複製之抑制劑 |
| AR112412A1 (es) | 2017-08-17 | 2019-10-23 | Gilead Sciences Inc | Formas de sal de colina de un inhibidor de la cápside del vih |
| TWI687415B (zh) | 2017-08-17 | 2020-03-11 | 美商基利科學股份有限公司 | Hiv蛋白質膜抑制劑之固體形式 |
| JP7083398B2 (ja) | 2018-02-15 | 2022-06-10 | ギリアード サイエンシーズ， インコーポレイテッド | ピリジン誘導体およびｈｉｖ感染を処置するためのその使用 |
| EP3752496B1 (en) | 2018-02-16 | 2023-07-05 | Gilead Sciences, Inc. | Methods and intermediates for preparing a therapeutic compound useful in the treatment of retroviridae viral infection |
| EP3774775B8 (en) * | 2018-04-11 | 2023-11-15 | VIIV Healthcare UK (No.5) Limited | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication |
| JP7433303B2 (ja) * | 2018-09-20 | 2024-02-19 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| EP3873607B1 (en) * | 2018-10-29 | 2023-11-29 | VIIV Healthcare UK (No.5) Limited | Quinazolinyl-indazole derivatives and their use as inhibitors of human immunodeficiency virus replication |
| JP2022506399A (ja) * | 2018-11-05 | 2022-01-17 | ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド | ヒト免疫不全ウイルス複製の阻害剤 |
| US20210395248A1 (en) * | 2018-11-05 | 2021-12-23 | VIIV Healthcare UK (No.5) Limited | Inhibitors of human immunodeficiency virus replication |
| UY38559A (es) * | 2019-02-01 | 2020-07-31 | Viiv Healthcare Uk No 5 Ltd | Inhibidores de la replicación del virus de la inmunodeficiencia humana |
| BR112021025655A2 (pt) * | 2019-06-19 | 2022-02-01 | Viiv Healthcare Uk No 5 Ltd | Inibidores da replicação do vírus da imunodeficiência humana |
| JP7703538B2 (ja) * | 2019-12-09 | 2025-07-07 | ヴィーブ、ヘルスケア、カンパニー | カボテグラビルを含んでなる医薬組成物 |
-
2021
- 2021-03-03 KR KR1020227034569A patent/KR20220151655A/ko active Pending
- 2021-03-03 AU AU2021231447A patent/AU2021231447A1/en not_active Abandoned
- 2021-03-03 JP JP2022553213A patent/JP2023517043A/ja active Pending
- 2021-03-03 US US17/802,194 patent/US20230355626A1/en active Pending
- 2021-03-03 MX MX2022011016A patent/MX2022011016A/es unknown
- 2021-03-03 BR BR112022017832A patent/BR112022017832A2/pt unknown
- 2021-03-03 EP EP21710351.4A patent/EP4114834A1/en not_active Withdrawn
- 2021-03-03 CN CN202180032445.6A patent/CN115551858A/zh active Pending
- 2021-03-03 CA CA3170536A patent/CA3170536A1/en active Pending
- 2021-03-03 IL IL296182A patent/IL296182A/en unknown
- 2021-03-03 WO PCT/IB2021/051764 patent/WO2021176366A1/en not_active Ceased
-
2022
- 2022-09-05 CL CL2022002405A patent/CL2022002405A1/es unknown
-
2024
- 2024-03-15 AU AU2024201719A patent/AU2024201719A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA3170536A1 (en) | 2021-09-10 |
| CN115551858A (zh) | 2022-12-30 |
| EP4114834A1 (en) | 2023-01-11 |
| US20230355626A1 (en) | 2023-11-09 |
| JP2023517043A (ja) | 2023-04-21 |
| WO2021176366A1 (en) | 2021-09-10 |
| AU2024201719A1 (en) | 2024-04-04 |
| CL2022002405A1 (es) | 2023-04-14 |
| IL296182A (en) | 2022-11-01 |
| KR20220151655A (ko) | 2022-11-15 |
| MX2022011016A (es) | 2022-11-30 |
| AU2021231447A1 (en) | 2022-09-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022017832A2 (pt) | Inibidores de replicação do vírus da imunodeficiência humana | |
| EA202190854A1 (ru) | Ингибиторы репликации вируса иммунодефицита человека | |
| BR112021025655A2 (pt) | Inibidores da replicação do vírus da imunodeficiência humana | |
| BR112017022605A2 (pt) | ?composto, composição, e, método para tratamento de infecção por hiv?. | |
| BR112017022544A2 (pt) | ?composto, composição, e, método para tratamento de infecção por hiv?. | |
| UY37710A (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| UY38559A (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| BR112022025037A2 (pt) | Compostos antivirais para tratar infecções por coronavírus, picornavírus e norovírus | |
| BR112022004424A2 (pt) | Pró-fármacos antivirais e formulações dos mesmos | |
| BR112022006279A2 (pt) | Heteroaril-bifenil aminas para o tratamento de doenças pd-l1 | |
| BR112021020285A2 (pt) | Métodos e composições para degradação de proteína alvejada | |
| BR112017017500A2 (pt) | derivado de quinolina para uso no tratamento e prevenção de infecções virais | |
| BR112013026345A2 (pt) | composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv | |
| BR112018002689A2 (pt) | composto, composição útil e método para tratamento de infecção por hiv | |
| BR112023000142A2 (pt) | Derivados de benzodiazepina úteis no tratamento de infecção pelo vírus sincicial respiratório | |
| BR112023016970A2 (pt) | Compostos heterocíclicos antivirais | |
| BR112017028456A2 (pt) | composto, e, método de prevenção e/ou tratamento de hiv | |
| UY40000A (es) | Inhibidores del sars-cov-2 para tratar infecciones por coronavirus | |
| BR112023016986A2 (pt) | Compostos de aminopirimidina e métodos de seu uso | |
| CL2024001073A1 (es) | Inhibidores de la replicación del virus de inmunodeficiencia humana | |
| MX2025013861A (es) | Compuestos anti virus de la inmunodeficiencia humana (vih) | |
| UY37555A (es) | Derivados de ácido piridin-3-il-acético como inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| BR112018002678A2 (pt) | composto, composição, e, método para tratar infecção por hiv | |
| BR112018003181A2 (pt) | composto, composição, e, método para tratar infecção por hiv | |
| BR112023025850A2 (pt) | Inibidores da nicotinamida ripk1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122024005456-6 PROTOCOLO 870240023781 EM 19/03/2024 18:56. |
|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |